Head to Head Contrast: Neuphoria Therapeutics (NEUP) vs. Its Rivals

Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Neuphoria Therapeutics to similar companies based on the strength of its analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Insider and Institutional Ownership

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Neuphoria Therapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuphoria Therapeutics 1 2 0 0 1.67
Neuphoria Therapeutics Competitors 9920 15335 45741 1601 2.54

Neuphoria Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 201.72%. As a group, “Biotechnology” companies have a potential upside of 110.14%. Given Neuphoria Therapeutics’ higher possible upside, equities research analysts plainly believe Neuphoria Therapeutics is more favorable than its rivals.

Profitability

This table compares Neuphoria Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neuphoria Therapeutics N/A -2.74% -2.31%
Neuphoria Therapeutics Competitors -12,516.26% -215.37% -31.41%

Volatility & Risk

Neuphoria Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics’ rivals have a beta of -1.85, suggesting that their average share price is 285% less volatile than the S&P 500.

Earnings and Valuation

This table compares Neuphoria Therapeutics and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Neuphoria Therapeutics $1.17 million -$13.45 million -0.37
Neuphoria Therapeutics Competitors $690.26 million $7.76 million -18.38

Neuphoria Therapeutics’ rivals have higher revenue and earnings than Neuphoria Therapeutics. Neuphoria Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Neuphoria Therapeutics rivals beat Neuphoria Therapeutics on 7 of the 13 factors compared.

About Neuphoria Therapeutics

(Get Free Report)

Neuphoria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions. The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies. Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.

Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.